Divergent distribution of HIV-1 drug-resistant variants on and off antiretroviral therapy

Antiviral Therapy

Volumn 7, Issue 4, 2002, Pages 245-250

  Venturi, Giulietta ^a   Romano, Laura ^a   Carli, Tiziana ^b   Corsi, Paola ^c   Pippi, Luigi ^d   Valensin, Pier E ^a   Zazzi, Maurizio ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b UO Malattie Infettive Grosseto   (Italy)

^c UO Malattie Infettive   (Italy)

^d UO Malattie Infettive Siena   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; VIRUS DNA; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ANTIBIOTIC RESISTANCE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG WITHDRAWAL; EARLY DIAGNOSIS; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MONONUCLEAR CELL; PRIORITY JOURNAL; REBOUND; TREATMENT FAILURE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DNA, VIRAL; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MUTATION; RNA, VIRAL;

EID: 0036975006     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Devereux HL, Youle M, Johnson MA & Loveday C. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS 1999; 13:F123-F127.
2. Verhofstede C, Wanzeele FV, Van Der Gucht B, De Cabooter N & Plum J. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype. AIDS 1999; 13:2541-2546.
3. Miller V, Sabin C, Hertogs K, Bloor S, Martinez-Picado J, D'Aquila R, Larder B, Lutz T, Gute P, Weidmann E, Rabenau H, Phillips A & Staszewski S. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS 2000; 14:2857-2867.
4. Izopet J, Massip P, Souyris C, Sandres K, Puissant B, Obadia M, Pasquier C, Bonnet E, Marchou B & Puel J. Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen. AIDS 2000; 14:2247-2255.
5. Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, Hellmann NS, Petropoulos CJ, McCune JM, Hellerstein MK & Grant RM. Virologic and immunologic consequences of discontinuing combination antiretroviraldrug therapy in HIV-infected patients with detectable viremia. New England Journal of Medicine 2001; 344:472-480.
6. Zazzi M, Riccio ML, Venturi G, Catucci M, Romano L, De Milito A & Valensin PE. Long-read direct infrared sequencing of crude PCR products for prediction of resistance to HIV-1 reverse transcriptase and protease inhibitors. Molecular Biotechnology 1998; 10:1-8.
7. Shafer RW, Jung DR, Betts BJ, Xi Y & Gonzales MJ. Human immunodeficiencv virus reverse transcriptase and protease sequence database. Nucleic Acids Research 2000; 28:346-348.
8. Smith MS, Koerber KL & Pagano JS. Zidovudine-resistant human immunodeficiency virus type 1 genomes detected in plasma distinct from viral genomes in peripheral blood mononuclear cells. Journal of Infectious Diseases 1993; 167:445-448.
9. Kozal MJ, Shafer RW, Winters MA, Katzenstein DA & Merigan TC. A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. Journal of Infectious Diseases 1993; 167:526-532.
10. Kaye S, Comber E, Tenant-Flowers M & Loveday C. The appearance of drug resistance-associated point mutations in HIV type 1 plasma RNA precedes their appearance in proviral DNA. AIDS Research and Human Retroviruses 1995; 11:1221-1225.
11. Gunthard HF, Wong JK, Ignacio CC, Guatelli JC, Riggs NL, Havlir DV & Richman DD. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. Journal of Virology 1998; 72:2422-2428.
12. Devereux HL, Loveday C, Youle M, Sabin CA, Burke A & Johnson M. Substantial correlation between HIV type 1 drug-associated resistance mutations in plasma and peripheral blood mononuclear cells in treatment-experienced patients. AIDS Research & Human Retroviruses 2000; 16:1025-1030.
13. Hance AJ, Lemiale V, Izopet J, Lecossier D, Joly V, Massip P, Mammano F, Descamps D, Brun-Vezinet F & Clavel F. Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy. Journal of Virology 2001; 75:6410-6417.
14. Albrecht D, Zollner B, Feucht HH, Lorenzen T, Laufs R, Stoehr A & Plettenberg A. Reappearance of HIV multidrug-resistance in plasma and circulating lymphocytes after reintroduction of antiretroviral therapy. J1ournal of Clinical Virology 2002; 24:93-98.
15. Devereux HL, Emery VC, Johnson MA & Loveday C. Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutations. Journal of Medical Virology 2001; 65:218-224.
16. Birk M, Svedhem V & Sonnerborg A. Kinetics of HIV-1 RNA and resistance-associated mutations after cessation of antiretroviral combination therapy. AIDS 2001; 15:1359-1368.